July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
CHRONIC ORAL TREATMENT WITH BIO201 PRESERVES RETINAL FUNCTION IN A DRY AMD EXPERIMENTAL MODEL
Author Affiliations & Notes
  • Valerie Fontaine
    Institut de la Vision, Paris, France
  • Elodie Monteiro
    Institut de la Vision, Paris, France
  • Elena Brazhnikova
    Institut de la Vision, Paris, France
  • Mylene Fournie
    Institut de la Vision, Paris, France
  • Christine Balducci
    Biophytis, Paris, France
  • Louis Guibout
    Biophytis, Paris, France
  • Jose A. Sahel
    Institut de la Vision, Paris, France
  • Stanislas Veillet
    Biophytis, Paris, France
  • Pierre Dilda
    Biophytis, Paris, France
  • René Lafont
    Biophytis, Paris, France
  • Footnotes
    Commercial Relationships   Valerie Fontaine, Biophytis (F), Biophytis (P); Elodie Monteiro, BIOPHYTIS (F); Elena Brazhnikova, Biophytis (F); Mylene Fournie, BIOPHYTIS (F); Christine Balducci, BIOPHYTIS (E); Louis Guibout, BIOPHYTIS (E); Jose Sahel, Biophytis (P), BIOPHYTIS (S); Stanislas Veillet, Biophytis (E), Biophytis (P), BIOPHYTIS (I); Pierre Dilda, BIOPHYTIS (E); René Lafont, Biophytis (E), Biophytis (P), BIOPHYTIS (I)
  • Footnotes
    Support  Biophytis
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 241. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Valerie Fontaine, Elodie Monteiro, Elena Brazhnikova, Mylene Fournie, Christine Balducci, Louis Guibout, Jose A. Sahel, Stanislas Veillet, Pierre Dilda, René Lafont; CHRONIC ORAL TREATMENT WITH BIO201 PRESERVES RETINAL FUNCTION IN A DRY AMD EXPERIMENTAL MODEL. Invest. Ophthalmol. Vis. Sci. 2018;59(9):241.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We have recently demonstrated the potential of BIO201, a PPAR ligand entering clinical development, on retinal pigmented epithelium (RPE) and retina photoprotection in vitro and in vivo. Here we demonstrate that chronic BIO201 oral administration to a mouse model of dry AMD can slow down or stop the pathological features when used as preventive or curative treatment.

Methods : Experiments were performed using the Abca4-/-Rdh8-/- transgenic mouse model of dry AMD. Young mice (6-week-old males; n=10) were used to test BIO201 as a preventive treatment and older mice (12-month-old males, n=7 and females, n=10) to test it as a curative treatment. Mice were fed daily with BIO201 (a pharmaceutical grade norbixin) supplemented (0.5 g/kg) food or regular regimen for 5 or 6 months. Full field scotopic and photopic electroretinogram (ERG) were measured at the end of the treatment. One eye was collected for A2E measurement, and the second was used for histological analyses. Photoreceptor nuclei quantification was performed on eye cryosections. Bioavailability of BIO201 was measured in all mice by HPLC-MS/MS. Statistical analyses were performed using either a t test or a one-way ANOVA followed by Dunnett’s test.

Results : In the preventive experiment BIO201 significantly maintained the scotopic ERG a-wave (82% vs 62% for control compared to 6 week-old mice; p<0.01). A2E accumulation was reduced by 22% (p<0.01). In the curative experiment, BIO201 completely preserved the scotopic ERG a-wave and protected most of the residual photoreceptors in females but not in males. No difference was measured for the photopic ERG after either preventive or curative treatments. The sex differences appear to be related to the mouse model itself rather than to the molecule. Old male mice showed an accelerated kinetics of age-related A2E accumulation in the eyes and a more deteriorated ERG before treatment. At 1 year of age, A2E level was higher in males compared to females (230.4 ± 11.5 vs 192.9 ± 6.3 pmol/eye, p<0.05) whereas ERG a-wave was lower (-103.3 ± 5.8 vs -115.7 ± 6.3 µV, p<0.05). Males also showed a reduced BIO201 bioavailability as compared to females.

Conclusions : Oral administration of BIO201 (ca. 50 mg.kg-1.d-1) provides a significant protection to the retina. These results support the clinical development of BIO201 for dry AMD prevention and treatment.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×